RxDoctor Payments Data

Kelly Calkins, PA

Physician Assistant · Camarillo, CANPI 1689823718

Payments from drug & device makers

$1,689in general payments, 2019–2025

Across 91 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$689
  • AstraZeneca$237
  • Novo Nordisk$160
  • GSK$152
  • Pfizer$138
  • Lilly USA, LLC$101
  • plus $212 from 4 others

What the payments were for

  • Food & beverage$1,689100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen49$689
AstraZeneca13$237
Novo Nordisk8$160
GSK3$152
Pfizer6$138
Lilly USA, LLC5$101
AbbVie1$91
Exact Sciences2$45
Merck2$38
Shield Therapeutics Inc2$38

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,689 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$64,869
Medicare patients
195
Services billed
1,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nucynta ErTapentadol Hcl13$35,163
OzempicSemaglutide26$27,623
JardianceEmpagliflozin19$26,325
EliquisApixaban12$14,814
FarxigaDapagliflozin Propanediol13$14,058
OxycontinOxycodone Hcl12$6,557
Buprenorphine24$3,990
Levothyroxine Sodium104$3,391
Albuterol Sulfate HfaAlbuterol Sulfate90$2,735
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen76$2,338
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen64$1,957
Gabapentin113$1,687
Atorvastatin Calcium131$1,510
Duloxetine Hcl36$1,390
Omeprazole67$1,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$160$27,62326 claims
PfizerEliquis$138$14,81412 claims
AstraZenecaFarxiga$237$14,05813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Camarillo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →